This research reports synthesis and binding analysis of SOS1 ligands in KRAS-driven cancers, indicating a potential therapeutic approach.
High Resolution Image Download MS PowerPoint Slide SOS1 is a guanine nucleotide exchange factor that promotes KRAS activation by catalyzing GDP release and GTP loading, making SOS1-mediated nucleotide exchange an attractive therapeutic target in KRAS-driven cancers. Herein, we report the synthesis, biophysical characterization, and structural analysis of aminobenzo[ d ]isothiazole 1,1-dioxide SOS1 ligands. Compound 6f engaged SOS1 with a K D of 570 nM by microscale thermophoresis, supported by surface plasmon resonance. X-ray crystal structures of SOS1 bound to compounds 6b and 6f refined previous binding hypotheses regarding pocket engagement. Rather than being dominated by sulfone-mediated contacts, SOS1 recognition is primarily driven by hydrophobic and aromatic packing within the canonical pocket, a conserved ligand NH hydrogen bond to Asn879, and π-π stacking with Tyr884, recapitulating key features of BI-3406 binding. Comparative analysis further delineates vector requirements for productive engagement of KRAS-facing regions, providing a structure-based framework for future optimization of aminobenzo[ d ]isothiazole 1,1-dioxide SOS1 ligands.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: